Inflammatory bowel disease in pediatrics and its particularities
report of 6 cases with clinical presentation variants
DOI:
https://doi.org/10.47456/rbps.v26i1.51132Keywords:
Ulcerative colitis, Crohn's disease, Inflammatory bowel disease, Early-onset inflammatory bowel disease, PediatricsAbstract
Introduction: Inflammatory Bowel Diseases (IBD) are chronic and idiopathic diseases that involve an inflammatory process in the gastrointestinal tract, with periods of exacerbation and remission. They include Crohn's Disease (CD) and Ulcerative Colitis (UC). In pediatrics, they present with initial symptoms of greater severity and extent. In recent years, there has been an increase in incidence among younger children and, despite the early onset, most are diagnosed at later stages. The objective of this study is to present a series of cases of children and adolescents with IBD, admitted in 2023 to the pediatric ward of a university hospital in Espírito Santo. Six patients were selected, 3 females and 3 males, 2 diagnosed with UC, 3 with CD, and 1 with very early onset IBD. Ages ranged from 10 months to 16 years. Discussion: Given the increased incidence of IBD in the pediatric age group, its more severe presentation in childhood and its chronic evolution, early diagnosis becomes essential, but due to the different forms of clinical presentation, difficulties in making an adequate diagnosis may occur. Conclusion: The description of the particularities of each clinical case presented in this work can contribute to the development of more effective actions related to the comprehensive care of children with IBD. This includes promoting early diagnosis and implementing rapid and effective interventions, minimizing the impact on the quality of life of patients and their families.
Downloads
References
M’Koma AE. Inflammatory bowel disease: clinical diagnosis and surgical treatment—overview. Medicina (Kaunas). 2022 Apr 21;58(5):567. https://doi.org/10.3390/medicina58050567. PMID: 35629984; PMCID: PMC9144337
Conrad MA, Kelsen JR. The treatment of pediatric inflammatory bowel disease with biologic therapies. Curr Gastroenterol Rep. 2020 Jun 15;22(8):36. https://doi.org/10.1007/s11894-020-00773-3. PMID: 32542562; PMCID: PMC8094805
Lomazi EA, Oba J, et al. Brazilian consensus on the management of inflammatory bowel diseases in pediatric patients: a consensus of the Brazilian Organization for Crohn’s Disease and Colitis (GEDIIB). Arq Gastroenterol. 2023 Mar 24;59(Suppl 1):85–124. https://doi.org/10.1590/S0004-2803.2022005S1-04. PMID: 36995890
Kuenzig ME, Fung SG, Benchimol EI; InsightScope Pediatric IBD Epidemiology Group. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022 Apr;162(4):1147–59.e4. https://doi.org/10.1053/j.gastro.2021.12.282. Epub 2022 Jan 5. PMID: 34995526
Ashton JJ, Beattie RM. Inflammatory bowel disease: recent developments. Arch Dis Child. 2024 Apr 18;109(5):370–6. https://doi.org/10.1136/archdischild-2023-325668. PMID: 37468139; PMCID: PMC11056939
Ricciuto A, Mack DR, et al. Diagnostic delay is associated with complicated disease and growth impairment in paediatric Crohn’s disease. J Crohns Colitis. 2021 Mar 5;15(3):419–31. https://doi.org/10.1093/ecco-jcc/jjaa197. PMID: 32978629; PMCID: PMC7944510
Bordin J, Coronel J, et al. P064 Clinical aspects of pediatric inflammatory bowel disease: a multicentric study from Brazil. Am J Gastroenterol. 2020 Dec;115(Suppl):S16–7. https://doi.org/10.14309/01.ajg.0000723052.46502.a9
Maaser C, Sturm A, Vavricka SR, et al. ECCO–ESGAR guideline for diagnostic assessment in IBD. Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019 Feb 1;13(2):144–64. https://doi.org/10.1093/ecco-jcc/jjy113. PMID: 30137275
Ricciuto A, Fish JR, et al. Diagnostic delay in Canadian children with inflammatory bowel disease is more common in Crohn’s disease and associated with decreased height. Arch Dis Child. 2018 Apr;103(4):319–26. https://doi.org/10.1136/archdischild-2017-313060. Epub 2017 Aug 9. PMID: 28794097
Singer AAM, Bloom DA, Adler J. Factors associated with development of perianal fistulas in pediatric patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021 May;19(5):1071–3. https://doi.org/10.1016/j.cgh.2020.04.060. Epub 2020 Apr 30. PMID: 32360805
Maia MM, Souza IH, et al. Intervenções cirúrgicas no tratamento de fístulas retovaginais em pacientes com doença de Crohn: abordagem multidisciplinar em ginecologia e cirurgia plástica. Rev Iberoam Humanid Cienc Educ. 2024;10(10):649–60. https://doi.org/10.51891/rease.v10i10.15927
Albuquerque IC, et al. Fístula retovaginal na doença de Crohn: qual é a abordagem terapêutica em um centro de referência? J Coloproctol (Rio J). 2017;37:25–30.
Hall CHT, de Zoeten EF. Understanding very early onset inflammatory bowel disease (VEOIBD) in relation to inborn errors of immunity. Immunol Rev. 2024 Mar;322(1):329–38. https://doi.org/10.1111/imr.13302. Epub 2023 Dec 19. PMID: 38115672; PMCID: PMC11044353
Bharadwaj S, Narula N, Tandon P, Yaghoobi M. Role of endoscopy in inflammatory bowel disease. Gastroenterol Rep (Oxf). 2018 May;6(2):75–82. https://doi.org/10.1093/gastro/goy006. Epub 2018 Mar 9. PMID: 29780594; PMCID: PMC5952948
Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021 Jul;161(1):47–65. https://doi.org/10.1053/j.gastro.2021.04.063. Epub 2021 Apr 30. PMID: 33940007; PMCID: PMC8640961
Reznikov EA, Suskind DL. Current nutritional therapies in inflammatory bowel disease: improving clinical remission rates and sustainability of long-term dietary therapies. Nutrients. 2023 Jan 28;15(3):668. https://doi.org/10.3390/nu15030668. PMID: 36771373; PMCID: PMC9920576
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
